Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 24 Publications

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MWnGeY5kfGmxbjDBd5NigQ>? NEPqXWYxNjgQvF2= NInodlUzPGh? NYPUSY9O\XSqYX7vcC=> NVjuRotm\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= NWTw[4diOjV5OEewO|k>
TE13 MYnGeY5kfGmxbjDBd5NigQ>? MnvYNE4{|ryP NX[5cXhxOjSq NF\LVYp2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> NHS5fFIzPTV5OU[2OS=>
TE13 MVzBdI9xfG:|aYOgRZN{[Xl? MnHGNE4{|ryP MoHRNlRp M3r0T4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25? M1LFO|I2PTd7Nk[1
MEFs NH\RclNHfW6ldHnvckBCe3OjeR?= NVf3OnBWPc7:TR?= MUexOog> NGfnbGdqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? MW[yOVQ5OjZ|NB?=
SW480  MUnGeY5kfGmxbjDBd5NigQ>? M3S4OVAvOc7:TR?= M3XX[VQ5cA>? M4\ISmROW09? NWW2W|loemW4ZYLz[ZMhTU2W NHHFZ3gzPTR|NEm5Oy=>
PC3  M4HSRWZ2dmO2aX;uJGF{e2G7 NITkUY8xNjIQvF2= NFXvOVM1QGh? M3\1d2ROW09? NX7qR2pUemW4ZYLz[ZMhTU2W M1fn[FI2PDN2OUm3
SW480  NInGUWhHfW6ldHnvckBCe3OjeR?= M3faNFAvOc7:TR?= M4LIelQ5cA>? M{DyO2ROW09? M{m3NIF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= NIfwO2IzPTR|NEm5Oy=>
PC3  M2jBW2Z2dmO2aX;uJGF{e2G7 NULDS5htOC5zzszN NVH5cFR5PDiq MXnEUXNQ NUXZOXRI[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MXGyOVQ{PDl7Nx?=
SW480  MXzGeY5kfGmxbjDBd5NigQ>? M1L6c|AvOc7:TR?= NHrEO5U1QGh? M1zu[GROW09? NHjvRZlqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ M4XNNlI2PDN2OUm3
PC3  MmTjSpVv[3Srb36gRZN{[Xl? M1i4PFAvOc7:TR?= NUGwVIN3PDiq M2OyXGROW09? NWHMbVZQcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= NXjDd4RXOjV2M{S5PVc>
A431 NHPvV|FCeG:ydH;zbZMhSXO|YYm= M{[2VVIwOTBxNUCvNVAxdk1? NFXDO201QGh? Mo\oSG1UVw>? MXrpcohq[mm2czD0bIUh[2WubDDndo94fGh? M3yzfVI2OzdzME[5
A431 NF\mNFFHfW6ldHnvckBCe3OjeR?= MV:1NI5O NYTSdmFXOi94L{GyM|I1cA>? M{\MTmROW09? M2foboFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= NVjYVpM1OjV|N{GwOlk>
MDA-MB-231 NEPodYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\SUY9COC14MEDuUS=> M{joVVI1cA>? NVi2SodKTE2VTx?= MXTJR|UxKG:oIEGwNI5O NX\Ob4lPOjVzOUK3NlE>
MCF7 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XTSVAuPjBybl2= NWO3UVFJOjSq M4C3dWROW09? MkLiTWM2OCCxZjC3OY5O MoHkNlUyQTJ5MkG=
SKOV-3 NUDvco9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXroUYhSOS1zMN88US=> M{PZTVI1cA>? M1\TXmROW09? MVrJR|UxKG:oIEWuOu69VQ>? Mn\SNlUyPjl2OUG=
A549 NXTlNWc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHnNU0yOM7:TR?= NEXuNG4zPGh? MWLEUXNQ M2X0XmlEPTBib3[gN{4z|ryP M4r6PFI2OTZ7NEmx
SKOV-3 NELFcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjuPIYxNjFvMd88US=> MknYOFhp Mn3QSG1UVw>? MXzJR|UxKG:oIECuO:69VQ>? MVSyOVE3QTR7MR?=
A549 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUmxUFZMOC5zLUJOwG0> M{jCNlQ5cA>? MYrEUXNQ NHfqRmlKSzVyIH;mJFAvOjkQvF2= Mkm0NlUyPjl2OUG=
SKOV-3 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LmZlAvODFvMD65{txO NIPRb5k4Omh? NU\2UVJQTE2VTx?= MWDJR|UxKG:oIECuN|LPxE1? MnTkNlUyPjl2OUG=
A549 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz0ZWQxNjBzLUCuPe69VQ>? M3LHOlczcA>? Mo[2SG1UVw>? NUfwelU6UUN3MDDv[kAxNjB4zszN NXS1WGk4OjVzNkm0PVE>
HeLa M1n2fWZ2dmO2aX;uJGF{e2G7 MU[yOVBvVQ>? MUKxOog> NW[wVJBuTE2VTx?= MnzvbY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= M{f1UlI2OTF4Nki4
CNE2 M2TPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vwN|ExOC14MEDuUS=> M2Dh[lI1NzR6L{eybC=> NUPrc5FCcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz MoK0NlQ6Pjl7MEG=
PC3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfpSJgyODBvMUCwNI5O MUiyOIg> MkS5TWM2OCCxZjCzNFBvVQ>? NYXRcWo1OjR6NUS2OVg>
LNCaP NH3aNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:xNFAuOTByMH7N Mmr2NlRp Mn7GTWM2OCCxZjCzNFBvVQ>? MlnQNlQ5PTR4NUi=
HeLa  MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;ZS|LPxE1? NYO3WmxqPDiq NXjVZmE3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIFjd3W2IEK1KS=> MUCyOFg1PjF|NR?=
HMEC-1  M1\QVGZ2dmO2aX;uJGF{e2G7 MnzSN|Axdk1? NUHW[Hd4OjSq NYT2ZXhvcW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? MXuyOFcyODZ|MR?=
HeLa M2\aVGZ2dmO2aX;uJGF{e2G7 MkTUNY1O MUWwMlVp Ml7GZYJwdGm|aHXzJJRp\SC2b4ThcEBJTEGFIHHjeIl3cXS7 NGnHV3MzPDdyN{S3OC=>
ACP02 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;qelFVOjVyL{O1NE82ODCwTR?= NF7pZ3AzPGh? NWPyUW1n\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= MkXkNlQ3Pjh3NEe=
ACP03 M3rGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiz[IYzPTBxM{WwM|UxOG6P M2r6cVI1cA>? NGH6epdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P MXuyOFY3QDV2Nx?=
U87 GBM MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7z[WsyODBxM{CwM|UxOCCwTR?= NUPCVmU2PzJiaB?= MX6xNFAmKGW2aHHuc4w> NIfuPZZz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> MmDpNlQ1PjR6NEG=
U87 GBM M4e0ZmZ2dmO2aX;uJGF{e2G7 MkPiNVAxNzVyMDDOcS=> M3j4VFQ5KGh? NHj2NmkyODBnIHX0bIFvd2x? NI\pc21KdmS3Y3XzJHNmdmW|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l? M4TwW|I1PDZ2OESx
RPE MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfaclNjOC5{L{CuOE8xNjhxMTFOwG0> NIC2R2czPC92OD:3NkBp NXPDVoRJTE2VTx?= MlqzbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q> NE\xSXkzPDR3Nk[wNi=>
HT29  NWqwOlVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DNSlE5OCCwTR?= NWLzZXVCPzJiaB?= NHS4bVhKSzVyIH;mJFE5OCCwTR?= Mn3XNlQ{Pjh{NkW=
hMSCs M1HjcWZ2dmO2aX;uJGF{e2G7 Mm\OOk4zPSCwTR?= NUXpPXVKOjRiaB?= NVK0Xlc2TE2VTx?= NGH1dGN{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz M4fCSFI1OzF{M{W2
Huh7  NEn0UW1HfW6ldHnvckBCe3OjeR?= Mlm0NE4yNzBwNT:xMlAh|ryP NEHsdXgzPGh? M4G4N5N2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= NXzBfopbOjR{Nkm2O|I>
SKOV3 NIfoZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6wMlA2NTJizszN MYGxNE8zPC92ODDo NXrlOZVqTE2VTx?= M4S1To1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NGfSRlIzPDJ{M{iwNS=>
A2780 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWwMlA2NTJizszN MVmxNE8zPC92ODDo NUnLSmhNTE2VTx?= M2SxeI1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NWnMXotWOjR{MkO4NFE>
SRA01/04  NFT6SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MleyNE4zKM7:TR?= Mlm0OFghcA>? NWGwXG1wTE2VTx?= NUSxU5Foe3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? MVSyOFE2Pzh5OB?=
HLEB3 MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XqUlAvOiEQvF2= NHX4PJU1QCCq MXLEUXNQ NUSzRYI2e3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? NVOxXGI5OjRzNUe4O|g>
SRA01/04  MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMlQwOC56IN88US=> MoTTOFghcA>? MoXzSG1UVw>? NV\3N3lkcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4HYZ|I1OTV5OEe4
HLEB3 NIm2NlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[wMlQwOC56IN88US=> MV20PEBp MVXEUXNQ M2e4b4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MYeyOFE2Pzh5OB?=
HCT116 NGnGUGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4X3e|AvOiEQvF2= MoPZNVIhcA>? NEjFSIdmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JJJi\GmjdHnvci=> NH7ERWozPDF{MkKzNS=>
CA46 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSzM|YwOTJxMkSvOFghdk1? NXHMN25SPDhiaB?= NID0cmJqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi NYiybHFHOjRyNkS5OVE>
PMNs NUnTTXJ5TnWwY4Tpc44hSXO|YYm= NF[0R2o{OCCwTR?= NX\X[Jo1PDhiaB?= MXzpcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= NXHnc3hKOjN7OEi2NVc>
H1299 M{nXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7WNeKh|ryPwrC= NX7OU4hJOjRxNEivO|IhcA>? MYfleIhidm:u MmntbY5kemWjc3XzJINmdGxiZHXheIgh[W[2ZYKgNlRp NXrxSHFDOjN7MU[2NFk>
A549 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT2N3NkOC5{NT:wMlUwOSEQvF2= M3rDclI1NzR6L{eyJIg> M3X6UoV1cGGwb3y= NXTDXlJycW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NWrpO4NjOjN6Nke5PVE>
H1299 Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm4NHJOOC5{NT:wMlUwOSEQvF2= Mli0NlQwPDhxN{KgbC=> MnPo[ZRp[W6xbB?= MWHpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NF74bXczOzh4N{m5NS=>
A549 M{TNVWFxd3C2b4Ppd{BCe3OjeR?= MkLkNE42NzFizszN NFPlPIg1QCCq Mn\k[ZRp[W6xbB?= NHWyOFRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoO5NlM5Pjd7OUG=
H1299 NE[2Z4NCeG:ydH;zbZMhSXO|YYm= NIfte48xNjVxMTFOwG0> MkOzOFghcA>? MVLleIhidm:u NGHzRZpqdmS3Y3XzJINmdGxiYYDvdJRwe2m| Ml\PNlM5Pjd7OUG=
SUM149PT M3jDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXlb5VQOi95LkWvNVAh|ryP NF2yTHM1QCCq MY\EUXNQ MVjpcoR2[2W|IHPlcIwh\GWjdHigZZQhOiEQvF2gbY5{\W6|aYTpeoVtgQ>? NXPOZodYOjN5OUK2N|g>
SUM190PT NFXGPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:4ZVUxNzFyMD:yOVAhdk1? M3j4R|Q5KGh? M2H5OmROW09? NEHMTYlqdmS3Y3XzJINmdGxiZHXheIgh[XRiNUCgcm0he2Wwc3n0bZZmdHl? MWmyN|c6OjZ|OB?=
HCT1 M2r5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPxPIQxNjJxMT6wM|UvOCEQvF2= MV6xNk8zPC9|Nj:0PEBp MV3pcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M4\lclI{PzdyMECw
Lovo NYLlb3ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\uOJgxNjJxMT6wM|UvOCEQvF2= M3\sOVEzNzJ2L{O2M|Q5KGh? M3;aWYlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NXq2UIZ1OjN5N{CwNFA>
AGS NIfITmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi5TYVUOC5yMUWtNUDPxE1? MWe3NkBp M4fpNIlv\HWlZYOgZ4VtdCCmZXH0bEBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NEX1TWIzOzd2NUCyOC=>
Huh7 NIrMPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUixJO69VQ>? MW[yOEBp M4\0WGROW09? NWfhRmxkemWmdXPld{Bi[m:3dDCyNEUhfmmjYnnsbZR6yqB? M3OyRVI{PjR|OUOz
ECC1 NXqyfJVQTnWwY4Tpc44hSXO|YYm= NYDRfXFtPTByIH7N NG[1Ro42KGR? MVPEUXNQ MlzabY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NUmzcmh5OjN3M{C3Olk>
HEC1A MUTGeY5kfGmxbjDBd5NigQ>? NHrYW4w2ODBibl2= MkXROUBl M{PBd2ROW09? NUXOOVJEcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NXLMOVZiOjN3M{C3Olk>
EN1 NXfmPJUyTnWwY4Tpc44hSXO|YYm= MV61NFAhdk1? MkHwOUBl MonPSG1UVw>? NInYO2ZqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= M4qwT|I{PTNyN{[5
MFE296 M373fGZ2dmO2aX;uJGF{e2G7 MnzzOVAxKG6P NFfYN|U2KGR? MlHNSG1UVw>? NVTFeFJ6cW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= MXWyN|U{ODd4OR?=
HASMCs NFHZVYJHfW6ldHnvckBCe3OjeR?= MofNNE02ODBibl2= NUj2UFJlPiCm NXfUXYVp\G:5bj3y[Yd2dGG2ZYOgeIhmKGW6cILld5Nqd25ib3[gTGFFSyCjbnSgZ4VtdCC4aXHibYxqfHl? Mm\DNlM2OTh2Nke=
U373 NET3e3VHfW6ldHnvckBCe3OjeR?= MX:wMlI2NzBwNT:xJO69VQ>? MmDuNlQhcA>? MYPpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? NUTheWYxOjN2N{SxO|E>
ARN8  MYXGeY5kfGmxbjDBd5NigQ>? MmTvNE4xPS1{IN88US=> NXTITpdIOjRiaB?= M1XCcZJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{ MUCyN|Q4ODV2MB?=
MCF7 MnX0SpVv[3Srb36gRZN{[Xl? NHm5OJUxNjB3LUKg{txO NFj1dlUzPCCq Ml;ZdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> M3fhWFI{PDdyNUSw
H1299  NXrjdnlqTnWwY4Tpc44hSXO|YYm= M2XlN|AvOzQkgKOxxsDDvU1? MUeyOE81QCCq NIjTbW5FVVOR Ml\sbY5kemWjc3XzJGUu[2GmaHXybY4heHKxdHXpckBt\X[nbIOg[I9{\SCmZYDlcoRmdnSueR?= NWHzUnVlOjN2NkG5O|U>
H1299 MU\GeY5kfGmxbjDBd5NigQ>? M1zMUlAvPSEQvF2= NGPRSmY1QCCq MVvEUXNQ MlHMbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> MVyyN|Q3OTl5NR?=
H1299 M{PCbGZ2dmO2aX;uJGF{e2G7 M33z[VAvPSEQvF2= M4r5flQ5KGh? NIrG[lJFVVOR MmPSbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? M1uwXFI{PDZzOUe1
MG-63  NFHPSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXiwMlMh|ryP MnPFNVIuQTZiaB?= NILNPY5FVVOR NWLCSHpqcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> MnrPNlM1PTF6MUe=
LM8 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzYNE4{KM7:TR?= NGf2dogyOi17NjDo NU\EbGNSTE2VTx?= NG\sUWhqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu NX\VPZdrOjN2NUG4NVc>
K562 NGTrdHVHfW6ldHnvckBCe3OjeR?= MXOwMlUh|ryP M1nTblI1KGh? NHi2[mhmfGijbn;s MYrk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NVPC[YpSOjN2M{C5OVc>
HEL NXj1cWVqTnWwY4Tpc44hSXO|YYm= MnjvNE42KM7:TR?= M1G2b|I1KGh? Mn3s[ZRp[W6xbB?= NI[2[W9l\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? NFXXc5kzOzR|MEm1Oy=>
HL60 M37pWGFxd3C2b4Ppd{BCe3OjeR?= NVTJ[m0yOSEQvF2= Mkn6NlQhcA>? M4jqdIlv\HWlZYRCpINmdGxiZHXheIg> NXW1[mtGOjN2MEC1NVk>
KG1 NH;UR49CeG:ydH;zbZMhSXO|YYm= MXSxJO69VQ>? M1zzVlI1KGh? Ml7QbY5lfWOnc9MgZ4VtdCCmZXH0bC=> NXHQWIlUOjN2MEC1NVk>
Kazumi MlvjRZBweHSxc3nzJGF{e2G7 M4PJeVEh|ryP M2HBO|I1KGh? MXPpcoR2[2W|wrDj[YxtKGSnYYTo NXn4XYhyOjN2MEC1NVk>
K562 NHvHXWZCeG:ydH;zbZMhSXO|YYm= NWXoSJZqOSEQvF2= M37tT|I1KGh? NIXMfnJqdmS3Y3XzxsBk\WyuIHTlZZRp MX[yN|QxODVzOR?=
THP1 MUTBdI9xfG:|aYOgRZN{[Xl? MoW0NUDPxE1? MoLSNlQhcA>? MYTpcoR2[2W|wrDj[YxtKGSnYYTo NFjHTZEzOzRyMEWxPS=>
SH-SY5Y MXPGeY5kfGmxbjDBd5NigQ>? NWm4eYVvOjVyIH7N NYXU[Y5bOTZiaB?= NFziXHdkcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW|aYOsJJVxfGGtZTDhcoQh\W[obIX4 NEi1T4YzOzN{NkSyNi=>
HEK293 NXnJdGZmTnWwY4Tpc44hSXO|YYm= MWixJOK2VcLi M3;k[FE5KGkEoB?= NIrMPJlqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| NUj1O5p4OjN{OES4OFg>
HTK MoPCSpVv[3Srb36gRZN{[Xl? M1jrTVQxOCCwTR?= M4jWelczKGh? NYfiSHE{cW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>? M4qxdVI{Ojh2MECy
HTK M4HiW2Z2dmO2aX;uJGF{e2G7 M2XMOVExOC16MEDuUS=> M1[xO|czKGh? M{fCUIJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w MoLHNlMzQDRyMEK=
Caco-2  MmT5SpVv[3Srb36gRZN{[Xl? NEPI[FMyKML3TdMg MYWyOEBp MkPs[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w MX2yN|E6PTB5MB?=
HeLa NIDtSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTrfVNFOTByIH7N NHfCWZczPCCq NUDnRlZUTE2VTx?= NVvnRnZrUUN3MDDv[kAyODCwTR?= M3:1UFI{OTZ3N{S4
HeLa NIrVTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj6OFAhdk1? MV[0PEBp NWGxUohOTE2VTx?= NELnb|hKSzVyIH;mJFQxdk1? MWSyN|E3PTd2OB?=
HeLa M{L2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4naUVIxKG6P M13VNlczKGh? MU\EUXNQ MmHtTWM2OCCxZjCyNI5O MXWyN|E3PTd2OB?=
HeLa M1LaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\LTmVbOTBxM{CvOVAhdk1? MmTkO|IhcA>? M4fp[mROW09? NFG5WVVqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDNUXAhMM7WzrjtLUBtd3O|IHPlcIx{KGSxc3Wg[IVx\W6mZX70cJk> MnTYNlMyPjV5NEi=
MDA-MB-231 M3L3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjxNlUuPDByIH7N M{DDTlQ5KGh? MYnJR|UxKG:oIEK2N{4zdk4EoB?= NXOxSmNuOjNyNUWxPVg>
MCF-7  Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zx[FI2NTRyMDDuUS=> NXjzXlBpPDhiaB?= MV\JR|UxKG:oIEKyNE41dk1? MWeyN|A2PTF7OB?=
ECC-1  NXvOR|dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfFS4JoOTByIH7N NX;2cZlpOjRiaB?= MWjleIhidm:u NYiycHZpcW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{Wl NVviNXNsOjNyMki4NFM>
HEC-1A M1HGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrPNVAxKG6P MlrLNlQhcA>? Mlnw[ZRp[W6xbB?= NFXwTHJqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= MlLVNlMxOjh6MEO=
NHAC-kn M1LvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXMR|UxOTBxMUCwM|UxOCCwTR?= NVnXU5pFOTJiaB?= MXHEUXNQ NUjzU4J7UUN3MDDv[kA2ODCwTR?= NVPHfFJsOjNyMUe4O|E>
A549 NFf4U|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnJNlUxKG6P MXW2MVczKGh? MnTrSG1UVw>? NV60cVdL[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? NGPYOowzOjl7NEe4NC=>
MG-63 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7vOGRsOzByIH7N MYWxNkBp NFfRNJJFVVOR MXnpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm MnPsNlI4QTl|M{i=
MG-63 NGfHeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv5dXE{ODBibl2= M4CxfFI1KGh? M2HWUmROW09? NGf3bpdqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn NXvmd2w2OjJ5OUmzN|g>
MG-63 NUG1[G0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2zNFAhdk1? M1njc|Q5KGh? M1PlVGROW09? M1K2NolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? NYjJTmNIOjJ5OUmzN|g>
HL60  NEPsRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXixOVAuOzVyIH7N NYexNXF1OjRiaB?= MU\pcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N M3S4flIzPzV|N{O5
U937 NGHabpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XDXVE2OC1|NUCgcm0> NWPY[4RPOjRiaB?= MnnlbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> MYKyNlc2Ozd|OR?=
SCC-6 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[yNFAuOzJyMDDuUS=> M1nhT|EzNzJ2L{S4JIg> M3W4R2ROW09? NUexSYdmcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NU\YXGpGOjJ3NUKzNlE>
U87  NEnXd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K5c|ExOC1|MECgcoc> NGXPW|MzPCCq MkL1bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFczLSBiYYSgNlAxdmd? MXSyNlI4ODh2OR?=
K562 NXO3N|Q1TnWwY4Tpc44hSXO|YYm= MUKxJO69VQ>? NVXoe2FnOTJiaB?= NYX4W|JvTE2VTx?= MVLlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= MmnXNlIyPzlzOUi=
Reh M4jZdGZ2dmO2aX;uJGF{e2G7 NWjVN2x1OC5|L{Gg{txO MWCxNkBp MnrqSG1UVw>? MYHlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= NGfB[mEzOjF5OUG5PC=>

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03839758 Not yet recruiting Shoulder Arthritis Université de Montréal May 2019 Not Applicable
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03858517 Not yet recruiting Shoulder Arthroplasty Stryker Trauma GmbH April 2019 --
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable
NCT03735173 Recruiting Arthropathy Shoulder|Shoulder Pain|Shoulder Osteoarthritis|Shoulder Arthritis|Shoulder Arthropathy Associated With Other Conditions|Necrosis of Bone|Arthritis|Inflammatory Arthritis Mayo Clinic December 1 2018 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID